Cognition Therapeutics Receives $16.6 Million Multiyear NIA Grant

Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a multiyear grant expected to total $16.6 million to support the Phase 2 SHINE study of Elayta™ (CT1812).

SHINE (Synaptic Health and Improvement of Neurological Function with Elayta) is a randomized, double-blind, placebo-controlled, parallel-group Phase 2 safety and efficacy study expected to enroll up to 160 adults with mild-to-moderate Alzheimer’s disease (MMSE 18-26). Cognition expects to initiate patient dosing in the SHINE study during the fourth quarter of 2018. SHINE will be conducted in two parts. Part A will enroll 24 adults who will receive Elayta at doses of 100 or 300 mg per day or placebo for 6 months. Part B will be initiated pending the successful completion of Part A and will randomize up to 134 additional individuals into the study with the same design and duration.